Trial Profile
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab/relatlimab (Primary) ; Sarilumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2023 Status changed from not yet recruiting to recruiting.
- 31 Oct 2022 Planned initiation date changed from 1 Sep 2022 to 1 Dec 2022.
- 04 Aug 2022 Planned initiation date changed from 1 Jul 2022 to 1 Sep 2022.